Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 8.5% from a year ago
Cash & equivalents stood at $175.68M at the end of Q2 FY2026, down 8.5% from a year earlier and down 7.5% from the prior quarter. Over 3 fiscal years it compounded at +10.5% a year.
Context
- Cash & equivalents amounted to 19.6% of total assets at the end of Q2 FY2026, down 9.4 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -8.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 165.6M USD
- Year-over-year change
- -9.8%
- 4-year CAGR
- +7.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 165.6M | -9.8% |
| FY2024 | 2024-12-31 | 183.58M | +70.1% |
| FY2023 | 2023-12-31 | 107.95M | -12.0% |
| FY2022 | 2022-12-31 | 122.72M | +0.2% |
| FY2021 | 2021-12-31 | 122.47M | — |
Cash & Equivalents vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's Jun 2026 cash & equivalents of $175.68M is the 5th highest of the 10 companies compared; the peer median is $110.55M.
- Its year-over-year change of -8.5% is the 8th highest of 10, against a peer median of +38.4%.
- Cash & equivalents amounts to 19.6% of total assets for KNSA, versus a peer median of 15.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $722.27M | +38.4% | +33.8% | 94.9% | |
| Aug 2026 | $720.24M | +818.2% | +56.5% | 60.3% | |
| Mar 2026 | $248.47M | +151.9% | +49.5% | 75.4% | |
ORKAOruka Therapeutics, Inc. | Sep 2026 | $191.52M | +109.9% | +3.4% | 15.6% |
| Jun 2026 | $175.68M | -8.5% | +10.5% | 19.6% | |
| Jun 2026 | $110.55M | +735.2% | +49.3% | 9.1% | |
| Sep 2026 | $82.73M | +27.5% | +35.0% | 7.5% | |
| Mar 2026 | $53.1M | -11.6% | -11.0% | 10.9% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
| Mar 2026 | $24.99M | -80.0% | +6.4% | 25.0% | |
| Peer median (excluding KNSA) | $110.55M | +38.4% | +33.8% | 15.6% | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 122.47M | 122.72M | 107.95M | 183.58M | 165.6M |
| Short-term Investments | 59.73M | 67.89M | 98.42M | 60.05M | 248.48M |
| Net Receivables | 3.99M | 20.32M | 21.27M | 41.72M | 15.59M |
| Inventory | 3.68M | 21.6M | 31.12M | 26.36M | 54.9M |
| Other Current Assets | 0 | 10.54M | 17.54M | 20.08M | 42.61M |
| Total Current Assets | 196.45M | 243.06M | 276.3M | 331.8M | 527.18M |
| Property, Plant & Equipment (Net) | 8.38M | 7.04M | 12.67M | 11.04M | 11.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 19.25M | 18.25M | 17.25M | 16.25M | 15.25M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 185.5M | 219.28M | 211.15M | 198.15M |
| Other Non-current Assets | 8.72M | 5.82M | 827K | 10.32M | 11.31M |
| Total Non-current Assets | 36.35M | 216.61M | 250.03M | 248.75M | 236.46M |
| Total Assets | 232.8M | 459.67M | 526.32M | 580.55M | 763.63M |
| Account Payables | 1.87M | 7.9M | 8.25M | 2.04M | 2.03M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.99M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 307K | 0 | 31.81M |
| Other Current Liabilities | 1.54M | 16.97M | 36.91M | 33.12M | 102.36M |
| Total Current Liabilities | 44.82M | 47.07M | 63.67M | 100.62M | 139.18M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 12M | 11.95M | 31.81M | 31.81M |
| Other Non-current Liabilities | 270K | 1.84M | 1.86M | 1.82M | 18.52M |
| Total Non-current Liabilities | 2.94M | 16.46M | 23.82M | 41.5M | 56.84M |
| Total Liabilities | 47.76M | 63.52M | 87.48M | 142.12M | 196.03M |
| Common Stock | 18K | 19K | 20K | 20K | 21K |
| Retained Earnings | (675.4M) | (492.03M) | (477.95M) | (521.14M) | (462.14M) |
| Accumulated OCI | (66K) | 44K | 6K | (163K) | (25K) |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 185.04M | 396.15M | 438.84M | 438.44M | 567.61M |
| Total Debt | 6.05M | 5.92M | 12.26M | 9.86M | 9.5M |
| Net Debt | (116.42M) | (116.8M) | (95.7M) | (173.73M) | (156.1M) |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.